Navigation Links
Bioniche Reports the Passing of its Board Chair
Date:4/18/2008

- Hy Isenbaum served as Chair of the Bioniche Board of Directors since 1999

-

BELLEVILLE, ON, April 18 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that its long-time Board Chair, Mr. Hy Isenbaum, has passed away.

"This is very sad news for Bioniche Life Sciences," said Graeme McRae, the Company's President & CEO. "As Board Chair, Mr. Isenbaum contributed financial expertise and vigilance regarding the Company's financial statements. Additionally, he has provided a high level, conservative, ethical tone that permeates the whole Company in terms of regulatory affairs, product development, and overall conduct of the business. He will be greatly missed by all who knew and worked with him. He was a mentor and a friend."

Mr. Isenbaum was Chair of the Board since 1999, when Bioniche Life Sciences Inc. was formed through an amalgamation of Bioniche Inc., Renaissance Life Sciences Inc., and Vetrepharm Animal Health Inc.

Mr. Isenbaum was a Fellow Chartered Accountant and the Founder of the firm Soberman, Isenbaum and Colomby. As the Managing Partner, a position he held until 1993, he built his firm to be the 15th largest accounting practice in Canada. He was a Chairman of the Board and Chairman Emeritus of the Mount Sinai Hospital in Toronto. He was appointed by the Ontario Ministry of Health as Ombudsman to the Medical Review Committee of the College of Physicians and Surgeons. He served on the Board of Directors of the Samuel Lumenfeld Research Institute in Toronto and was instrumental in the establishment of the Institute. Mr. Isenbaum was also a Governor of the Weizman Institute of Science in Israel and sat on the boards of a number of private and public companies.

In honour of Mr. Isenbaum's extensive contributions to Bioniche, the "Hy Isenbaum Award" has been created. This will be presented annually to the Bioniche employee who best epitomizes the Bioniche spirit - whether at work or in the community.

A new Chair will be appointed at the Board's next quarterly meeting in early May.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche has been named one of Canada's Top Ten Life Sciences Companies for 2008. For more information, please visit http://www.Bioniche.com.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.


'/>"/>
SOURCE Bioniche Life Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Converts a Portion of its Debt to Equity
2. Bioniche Receives Fast Track Designation For First-Line Bladder Cancer Therapy
3. Bioniche Pharma Chooses TrackWise for its Deviation Control Solution
4. Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin(TM)
5. Bioniche Reports Fiscal 2008 Second Quarter
6. USDA Agrees to Grant Conditional License to Bioniche for its E. coli O157:H7 Cattle Vaccine
7. Bioniche Amends Terms of Convertible Debt with Laurus Master Funds
8. Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario
9. Bioniche Reports Fiscal 2008 First Quarter
10. Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference
11. Media Advisory - Bioniche Discusses USDA Comment on E. coli O157:H7 Cattle Vaccine Field Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
Breaking Medicine Technology: